Eur J Pharmacol 179, 441-445, (1990). Monnet, F. P., Debonnel, G., Junien, J. L., & De Montigny, C. View abstract in PubMed Post navigationPreviousPrevious post:Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems.NextNext post:Evidence for an anti-amnesic effect of JO 1784 in the rat: A potent and selective ligand for the sigma receptor.Related PostsAnavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)August 26, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021Anavex Life Sciences Announces Closing of $50 Million Registered Direct OfferingJune 24, 2021
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)August 26, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021
